4//SEC Filing
Tatsis Ourania 4
Accession 0000950170-25-083227
CIK 0001840574other
Filed
Jun 5, 8:00 PM ET
Accepted
Jun 6, 5:00 PM ET
Size
5.7 KB
Accession
0000950170-25-083227
Insider Transaction Report
Form 4
Tatsis Ourania
Director
Transactions
- Award
Stock Option (right to buy)
2025-06-05+42,200→ 42,200 totalExercise: $5.73Exp: 2035-06-04→ Common Stock (42,200 underlying)
Footnotes (1)
- [F1]This stock option was issued pursuant to the 2021 Stock Incentive Plan of Verve Therapeutics, Inc. in accordance with its director compensation program. The vesting commencement date (the "Vesting Commencement Date") of the options is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or immediately prior to the first annual meeting of stockholders occurring after the grant date, in each case subject to the Reporting Person's continued service as a director.
Documents
Issuer
Verve Therapeutics, Inc.
CIK 0001840574
Entity typeother
Related Parties
1- filerCIK 0001789815
Filing Metadata
- Form type
- 4
- Filed
- Jun 5, 8:00 PM ET
- Accepted
- Jun 6, 5:00 PM ET
- Size
- 5.7 KB